The alkaloid that explains the difference
Natural kratom leaf contains roughly 40 documented alkaloids. Mitragynine is the dominant compound, typically 1–2% of dry leaf weight. 7-hydroxymitragynine is present at trace levels — usually less than 0.05% of dry leaf weight. So in a 3 g dose of standard leaf, you get roughly 30–60 mg of mitragynine and less than 1.5 mg of 7-OH.
7-OH is significantly more potent at the mu-opioid receptor than mitragynine — by some measures 10–46x more potent in receptor-binding affinity. In natural leaf, the trace quantity keeps its contribution modest relative to mitragynine's. In concentrated 7-OH products, the ratio inverts completely: 7-OH becomes the dominant active, and the effect profile shifts toward classical opioid pharmacology.
See our alkaloid comparison guide and science of mitragynine for the underlying chemistry.
How 7-OH products differ from natural leaf
- Alkaloid ratio: 7-OH-dominant vs. mitragynine-dominant
- Receptor pharmacology: stronger mu-opioid binding per dose, narrower receptor footprint, less of kratom's adrenergic and serotonergic components
- Effect profile: more strictly opioid-like, less of kratom's daytime functional character even at low doses
- Onset: typically faster — many 7-OH products are sublingual or fast-dissolving tablets, hitting in 5–15 minutes
- Duration: variable; some 7-OH products are short-acting (2–3 hours), others longer
- Dependence trajectory: faster and more severe than natural leaf at equivalent durations of use
- Withdrawal: more pronounced, closer to short-acting prescription opioid withdrawal
- Overdose risk: higher per dose than natural leaf, particularly when combined with other CNS depressants
The legal and policy picture
The AKA (American Kratom Association) has formally distinguished natural-leaf kratom from concentrated 7-OH products in its policy advocacy. The KCPA framework — see our KCPA explainer — specifically prohibits synthetic alkaloids and concentrated 7-OH products from the legal protections it advocates for. The reasoning: the things that make natural-leaf kratom defensible as a consumer botanical (relatively low dependence risk, low overdose risk, broad adult-use safety record) do not transfer to 7-OH-concentrated products.
Colorado's 2024 KCPA legislation and similar bills in other states have begun explicitly distinguishing the two categories. Federal regulatory action has been slower but trending in the same direction: the DEA has indicated potential scheduling for isolated 7-OH that would not affect natural-leaf kratom.
Why this matters for kratom's public perception
Much of the recent negative press about kratom — high-profile dependence stories, overdose case studies, ER visit reports — traces on closer reading to 7-OH products, not natural-leaf kratom. When news coverage conflates the two, it gives natural-leaf kratom a worse reputation than the underlying pharmacology supports, and it also understates the risk profile of 7-OH products specifically by attaching the kratom safety record to them.
Honest consumer advocacy requires holding the distinction. Honest regulatory policy requires holding the distinction. Honest vendor practice requires holding the distinction. Conflating them serves neither consumer safety nor product clarity.
What to look for to tell them apart at point of sale
- Label discloses 7-OH content as a percentage of total alkaloids. Natural leaf: under 5% typically. 7-OH-concentrated products: 50%+, sometimes 90%+.
- Per-dose 7-OH content in milligrams. Natural-leaf-equivalent doses deliver 1–5 mg 7-OH. 7-OH-concentrated products deliver 15–50 mg or more per dose.
- Product format. Pellets, tablets, "fast-acting shots," and sublingual products marketed for rapid relief are more likely to be 7-OH-concentrated. Powder, capsules, gummies, and beverages from full-spectrum leaf are typically natural-leaf.
- Marketing language. "Premium," "ultra," "enhanced," "concentrate," or "isolate" should trigger a closer look at the alkaloid breakdown. "Full-spectrum leaf" or "whole-leaf extract" usually signals natural-leaf product.
- AKA-qualified vendor. AKA-GMP-qualified vendors are typically natural-leaf focused. The AKA program explicitly excludes concentrated 7-OH products.
The 4 Leaf Herbals take
Everything we make is natural-leaf kratom — full alkaloid spectrum, with the dominant active being mitragynine. Our extracts concentrate the natural mitragynine plus supporting alkaloids, not isolated 7-OH. We support the KCPA framework's distinction between these two product categories because it is the line that keeps natural-leaf kratom legally defensible and consumer-safe. Browse the shop and check the lab results library to see the actual alkaloid breakdown on any product.
Frequently Asked Questions
What exactly is a '7-OH product'?
A '7-OH product' is a kratom-derived or kratom-adjacent product where the active ingredient is concentrated or isolated 7-hydroxymitragynine, rather than the full alkaloid spectrum of natural leaf. These appear under several names — '7-OH tablets,' '7-hydroxy shots,' 'premium enhanced kratom,' or sometimes just unlabeled 'extract pellets.' What makes them distinct from kratom is the dramatically elevated 7-OH content relative to mitragynine; natural leaf has 7-OH as a trace constituent, while these products may have 7-OH as the dominant active. The result is a product that behaves more like a pharmaceutical-grade opioid than like kratom.
Are 7-OH products legal?
Federally, the situation is contested. The DEA has indicated it may move to schedule isolated and concentrated 7-OH separately from natural-leaf kratom. The American Kratom Association's KCPA framework explicitly excludes synthetic 7-OH products from the kratom legal-protection it advocates for, and KCPA-aligned legislation in states like Colorado now prohibits concentrated 7-OH products specifically. The AKA's position is straightforward: protecting kratom legally means distinguishing it from synthetic or hyper-concentrated derivatives. See our <a href='/blog/kratom-consumer-protection-act'>KCPA explainer</a>.
Why are 7-OH products higher-risk than natural kratom?
Three reasons. First, 7-OH is a more potent mu-opioid receptor agonist than mitragynine — it binds more strongly and produces more pronounced opioid-like effects per molecule. Second, concentrating 7-OH removes the natural balance of supporting alkaloids that moderate kratom's effect profile. Third, the dose per pill or shot in 7-OH products often delivers more 7-OH than a user could realistically get from natural leaf — meaning the effective dose is in territory natural-leaf users would not reach. The combination of more potency, less buffering, and more concentrated dosing produces dependence and overdose risk closer to prescription opioids than to natural kratom.
Can 7-OH products be a tolerance reset?
Some users try them this way and the strategy is risky. The novel alkaloid pattern can produce effects when natural-leaf kratom has flattened, but 7-OH products build their own dependence and the dependence is more severe than the kratom dependence the user was trying to reset. The cleaner tolerance reset is a structured break — see our <a href='/blog/kratom-tolerance-and-rotation'>tolerance and rotation guide</a> — not a substance swap. Users who go from kratom to 7-OH and back often find their kratom dose has to climb significantly to compete with their new 7-OH baseline.
Does 4 Leaf Herbals sell 7-OH products?
No. We make natural-leaf kratom products — powder, capsules, extracts, gummies, and beverages — all derived from the full alkaloid spectrum of Mitragyna speciosa leaf. Our extracts concentrate mitragynine and the natural supporting alkaloids; we do not produce isolated or synthetic 7-OH products. This is a deliberate policy aligned with the AKA's KCPA position. See our <a href='/blog/synthetic-7-oh-products-explained'>synthetic 7-OH explainer</a> for the broader category context.